A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

Part of paid clinical trials in Redwood City, California.

Sponsor
Abeona Therapeutics, Inc
Study ID
NCT05708677
Status
Enrolling By Invitation

Conditions

  • RDEB

Eligibility Criteria

Sex
ALL
Age
6 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • EB-101 — BIOLOGICAL
    This is non-interventional and follows patients treated with EB-101

Study Details

A Long-Term Extension Study for Participants Previously Treated with EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Key Dates

Start date
Feb 9, 2021
Status verified
Jun 2024
Primary completion
Feb 29, 2036
Completion
Aug 31, 2036

Study Design

Enrollment
22 participants (estimated)

Arms

  • Arm: Long-Term Extension
    This study will follow one group of participants who were enrolled in a previous EB-101 study.

Primary Outcome Measure

Wound Closure [ Time Frame: 5 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Stanford UniversityRedwood CityCalifornia94063-
University of Massachusetts Medical SchoolWorcesterMassachusetts01605-

Find similar trials in Redwood City, CA

By research site
Stanford University· Redwood City, CAUniversity of Massachusetts Medical School· Worcester, MA